NVCR at a glance
NovoCure Ltd (NVCR, SEC CIK 1645113) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), NovoCure Ltd (NVCR) reported revenue of $655.4 million (up 8.3% from FY2024) and a net loss of $136.2 million. Diluted EPS was -$1.22.
- As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding NovoCure Ltd (NVCR) shares worth $721.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Brackmann Christoph on November 9, 2026 of 7,343 shares at $12.86 per share.
- In the last 90 days, NVCR insiders reported 0 open-market purchases ($0) and 3 open-market sales ($143K) on Form 4, a net sale of $143K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $655.4M
- +8.3% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$143K
- 13F holders
- 30 funds
- $721.2M · +1 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- FDA PMA approval dependency for Optune Gio sales; majority revenue from newly diagnosed and recurrent GBM indications
- Geopolitical risk from Greater China market reliance on Zai partnership for development and commercialization
- Production dependency on third-party manufacturers for sufficient quality and quantity of Products
- Competition risk from alternative therapies impacting market acceptance despite FDA and CE approvals
- Historical substantial operating losses with intermittent profits; ongoing high commercialization and R&D expenses
Management Discussion & Analysis
- Revenue and profitability details not provided in the provided MD&A excerpt
- Cash flow, capital allocation, and buybacks or dividends details absent
- Forward-looking guidance or emerging risks not mentioned in the excerpt
Business Overview
- Core business model: Commercialization of TTFields therapy devices (Optune Gio, Lua, Pax) delivering electric fields to kill cancer cells for solid tumor cancers
- New emphasis on brain metastases from NSCLC with September 2025 Phase 3 METIS trial showing 28% lower risk of intracranial progression; Optune Mya PMA submitted, FDA review ongoing
- Strategic expansion to pancreatic cancer with 2026 FDA approval of Optune Pax based on PANOVA-3 trial; survival improved to 16.2 vs 14.2 months (p=0.039)
- Sales force grew to 217 globally as of December 2025; estimated 8,200 GBM, 30,000 NSCLC, 15,000 pancreatic cancer patients in U.S. eligible and seeking treatment in 2026
- Unusual milestone: simultaneous regulatory progress with multiple devices; PMA filing acceptance for brain metastases (Optune Mya) and first U.S. approval for pancreatic cancer device Optune Pax
AI summary of the NVCR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risk factors disclosed in the 2025 10-K
- Carried-forward risks include regulatory, clinical, commercial, operational, and financial uncertainties
- No new or materially updated risk identified in the quarter
Management Discussion & Analysis
- Quarterly revenue $193.4M, up 16% YoY from $167.2M, driven by 19% global active-patient growth
- Gross margin 77% vs 73% YoY, with Optune Lua revenue $8.2M and Optune Pax revenue $3.7M
- Optune Pax fastest-growing product, $3.7M revenue vs $0.0M YoY; Optune Gio active patients 4,729
- Cash, equivalents and short-term investments $463.5M, up $15.8M from December 31, 2025
- Nine-month operating cash flow $17.3M vs $(31.0)M; tariff volatility and rising launch expenses remain headwinds
AI summary of the NVCR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- FDA Not Approvable Letter blocks Optune Mya approval for brain metastases from non-small cell lung cancer
- Regulatory rejection reflects uncertainty over clinical benefit, not safety concerns
Item EX-99.1: Item EX-99.1
- FDA Not Approvable Letter blocks Optune Mya approval for brain metastases from NSCLC after stereotactic radiation
- FDA cited uncertainty about clinical benefit, not safety concerns
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed results and management commentary
Item EX-99.1: Item EX-99.1
- Q3 revenue $193.4M, up 16% YoY, driven by 19% global active-patient growth to 5,260
- Gross margin 77% vs 73%, while adjusted EBITDA reached $15.7M and net loss narrowed to $10.4M
Item 7.01: Regulation FD Disclosure
- Japan MHLW approval expands Optune Pax® into unresectable locally advanced pancreatic cancer
- Approval covers adult patients receiving gemcitabine and nab-paclitaxel
AI summaries of NVCR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NVCR
Don't miss the next NVCR filing
- Alerts as it files. A push when NVCR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NVCR, by share count.
- Ask anything. An AI agent that reads every NVCR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Brackmann Christoph | Sell | Nov 9, 2026 | 7,343 | $12.86 |
| Paravasthu Mukund | Sell | Nov 9, 2026 | 3,079 | $12.86 |
| Puri Michal Nath | Sell | Nov 2, 2026 | 660 | $13.24 |
| Leonard Frank X | A | Jun 30, 2026 | 1,905 | $11.15 |
| Ben Arye Barak | A | Jun 30, 2026 | 1,299 | $11.15 |
| Danziger Asaf | A | Jun 30, 2026 | 268 | $11.15 |
| Puri Michal Nath | A | Jun 30, 2026 | 1,905 | $11.15 |
| Leonard Frank X | Sell | Jun 4, 2026 | 34,273 | $17.93 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $509.3M | $605.2M | $655.4M |
| Gross Profit | - | $468.0M | $488.5M |
| Operating Income | - | -$170.5M | -$153.8M |
| Net Income | - | -$168.6M | -$136.2M |
| Gross Margin | - | 77.3% | 74.5% |
| Op. Margin | - | -28.2% | -23.5% |
| Net Margin | - | -27.9% | -20.8% |
| Balance Sheet | |||
| Total Assets | - | $1.2B | $804.3M |
| Equity | $362.5M | $360.2M | $340.5M |
| ROE | - | -46.8% | -40.0% |
| Per Share | |||
| EPS | - | $-1.56 | $-1.22 |
| Cash Flow | |||
| Operating CF | - | -$26.4M | -$49.0M |
| CapEx | - | $42.9M | $26.6M |
Source: XBRL data in NovoCure Ltd (NVCR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate NVCR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 30 | $721.2M |
| Q2 2026 | 29 | $961.5M |
| Q1 2026 | 28 | $638.2M |
| Q4 2025 | 26 | $749.9M |
| Q3 2025 | 27 | $681.3M |
| Q2 2025 | 29 | $931.9M |
| Q1 2025 | 27 | $654.9M |
| Q4 2024 | 27 | $1.06B |
- AQR Capital Management+999.4K (+91%)
- Citadel Advisors LLC+288.1K (+183%)
- D.E. Shaw & Co+275.1K (+27%)
- Vanguard Portfolio Management LLC+221.3K (+4%)
- Morgan Stanley+174.7K (+4%)
- BlackRock−1.55M (-12%)
- JPMorgan Chase & Co−703.6K (-42%)
- Bank of America Corp−522.7K (-69%)
- Wells Fargo & Co−269.3K (-11%)
- Millennium Management−157.3K (-57%)
- FMR LLC (Fidelity)−17.37M
Source: 13F-HR filings on SEC EDGAR (aggregated from 223 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NVCR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Nov 4, 2026 | - | - | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 8-K | Sep 1, 2026 | - | Analysis | - |
| 8-K | Jul 23, 2026 | - | Analysis | - |
| 10-Q | Jul 23, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
NVCR SEC filings: frequently asked questions
Are NVCR insiders buying or selling?
In the last 90 days, NovoCure Ltd (NVCR) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $142,786 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold NVCR stock?
As of September 30, 2026, the largest NovoCure Ltd (NVCR) holders among the 13F filers tracked by SignalX were BlackRock ($189.2 million), Vanguard Portfolio Management LLC ($103.6 million), Vanguard Capital Management LLC ($78.5 million), Morgan Stanley ($74.9 million), State Street Corp ($46.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NVCR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), NovoCure Ltd (NVCR) reported revenue of $655.4 million (up 8.3% from FY2024) and a net loss of $136.2 million. Diluted EPS was -$1.22. The figures come from the XBRL data in the 10-K.
What are the main risks in NVCR's latest 10-K?
In the 10-K filed February 26, 2026, NovoCure Ltd (NVCR) flagged: FDA PMA approval dependency for Optune Gio sales; majority revenue from newly diagnosed and recurrent GBM indications. Geopolitical risk from Greater China market reliance on Zai partnership for development and commercialization. (AI summary of the Risk Factors section.)
What did NVCR report in its latest 8-K?
NovoCure Ltd (NVCR) filed an 8-K on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure). FDA Not Approvable Letter blocks Optune Mya approval for brain metastases from non-small cell lung cancer.
What are the latest NVCR SEC filings?
NovoCure Ltd (NVCR) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 12, 2026.
What is NVCR's SEC CIK number?
NovoCure Ltd (NVCR)'s SEC Central Index Key (CIK) is 1645113. EDGAR lists every NVCR filing under that number.
Ask anything about NVCR
The research agent reads NVCR's filings, financials, insider trades and 13F holders, then answers with sources.